Osteoporosis: intervention options

被引:5
作者
Netelenbos, C [1 ]
机构
[1] Free Univ Amsterdam Hosp, Dept Endocrinol, NL-1007 MB Amsterdam, Netherlands
关键词
osteoporosis; systemic progressive disease; fractures; postmenopausal women; estrogen; bisphosphonates;
D O I
10.1016/S0378-5122(98)00091-7
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Osteoporosis is a systemic progressive disease with important clinical complications because of the fractures that arise and cause major morbidity in especially the aging postmenopausal women. Because of the relative not complex procedure of diagnosis and prediction the most important question to answer. is treatment possible? There are now a variety of treatments available for the management of osteoporosis. The inhibitors of bone resorption, which include calcium, the vitamin Ds, bisphosphonates, calcitonins and gonadal steroids have been variously shown to prevent bone loss or to reduce fractures. On the other hand bone formation stimulating agents as fluorides and in the near future parathyroid hormone and analogues must be considered also. However, randomized clinical trials with fractures as clinical endpoints are only few in number and not present for every suggested treatment. During the last 3 years it has become clear that besides estrogen, bisphosphonates and now perhaps the selective estrogen receptor modulators also show a good alternative as intervention option of postmenopausal osteoporosis. At this moment sodium fluoride is not the first choice in treatment of osteoporosis in general practice. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:235 / 239
页数:5
相关论文
共 30 条
[1]   OPTIMAL CALCIUM INTAKE [J].
BILEZIKIAN, JP ;
BAILEY, L ;
ELMER, PJ ;
FAVUS, MJ ;
GO, VLW ;
GOLDRING, SR ;
HOLT, LH ;
INSOGNA, KL ;
KRIMGOLD, B ;
MALLETTE, LE ;
SHAPIRO, JR ;
STJEOR, ST ;
STERN, PH ;
TILLEY, BC ;
YAMAMOTO, ME .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (24) :1942-1948
[2]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[3]   Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: A meta-analysis of published clinical trials [J].
Cardona, JM ;
Pastor, E .
OSTEOPOROSIS INTERNATIONAL, 1997, 7 (03) :165-174
[4]   ESTROGEN REPLACEMENT THERAPY AND FRACTURES IN OLDER WOMEN [J].
CAULEY, JA ;
SEELEY, DG ;
ENSRUD, K ;
ETTINGER, B ;
BLACK, D ;
CUMMINGS, SR .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (01) :9-16
[5]  
Chang J, 1996, ANN ONCOL, V7, P671
[6]   EFFECT OF CALCIUM AND CHOLECALCIFEROL TREATMENT FOR 3 YEARS ON HIP-FRACTURES IN ELDERLY WOMEN [J].
CHAPUY, MC ;
ARLOT, ME ;
DELMAS, PD ;
MEUNIER, PJ .
BRITISH MEDICAL JOURNAL, 1994, 308 (6936) :1081-1082
[7]  
COL NF, 1997, JAMA-J AM MED ASSOC, V277, P313
[8]   Effect of calcium and vitamin D supplementation on bone, density in men and women 65 years of age or older [J].
DawsonHughes, B ;
Harris, SS ;
Krall, EA ;
Dallal, GE .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (10) :670-676
[9]   Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women [J].
Delmas, PD ;
Bjarnason, NH ;
Mitlak, BH ;
Ravoux, AC ;
Shah, AS ;
Huster, WJ ;
Draper, M ;
Christiansen, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (23) :1641-1647
[10]  
ELDERS PJM, 1994, J BONE MINER RES, V9, P963